AIMS: Vinflunine (VFL) ditartrate, a novel tubulin-targeted inhibitor, is registered for the treatment of patients with advanced or metastatic urothelial transitional cell carcinoma. This phase I study assessed the effect of renal impairment on the pharmacokinetics and tolerability of VFL. METHODS: VFL was infused in patients with advanced/metastatic solid tumours once every 3 weeks with anticipated dose reduction on the first cycle stratified according to the creatinine clearance (CLcr ) values. Pharmacokinetic data were collected on the first two cycles in renally impaired patients (CLcr ≤ 60 ml min(-1) ) and were compared with a control cohort of patients (CLcr > 60 ml min(-1) ). RESULTS: Thirty-three patients (46-86 years) were treated, 13 in group 1 (40 ml min(-1) ≤ CLcr ≤ 60 ml min(-1) ) and 20 in group 2 (20 ml min(-1) ≤ CLcr < 40 ml min(-1) ). The renal dysfunction induced a mean decrease in VFL clearance of 12% in group 1 and 28% in group 2, compared with the control group. The anticipated dose reduction given in renally impaired patients (i.e. 280 mg m(-2) and 250 mg m(-2) in groups 1 and 2, respectively) yielded similar drug exposure to control patients. The tolerance profile of VFL in patients with renal dysfunction was similar to that observed in patients with CLcr > 60 ml min(-1) . CONCLUSION: In conclusion, the recommended doses of intravenous VFL administered once every 3 weeks in cancer patients with renal impairment are 280 mg m(-2) when CLcr is between 40 and 60 ml min(-1) and 250 mg m(-2) when CLcr is between 20 and <40 ml min(-1) .
AIMS: Vinflunine (VFL) ditartrate, a novel tubulin-targeted inhibitor, is registered for the treatment of patients with advanced or metastatic urothelial transitional cell carcinoma. This phase I study assessed the effect of renal impairment on the pharmacokinetics and tolerability of VFL. METHODS:VFL was infused in patients with advanced/metastatic solid tumours once every 3 weeks with anticipated dose reduction on the first cycle stratified according to the creatinine clearance (CLcr ) values. Pharmacokinetic data were collected on the first two cycles in renally impaired patients (CLcr ≤ 60 ml min(-1) ) and were compared with a control cohort of patients (CLcr > 60 ml min(-1) ). RESULTS: Thirty-three patients (46-86 years) were treated, 13 in group 1 (40 ml min(-1) ≤ CLcr ≤ 60 ml min(-1) ) and 20 in group 2 (20 ml min(-1) ≤ CLcr < 40 ml min(-1) ). The renal dysfunction induced a mean decrease in VFL clearance of 12% in group 1 and 28% in group 2, compared with the control group. The anticipated dose reduction given in renally impaired patients (i.e. 280 mg m(-2) and 250 mg m(-2) in groups 1 and 2, respectively) yielded similar drug exposure to control patients. The tolerance profile of VFL in patients with renal dysfunction was similar to that observed in patients with CLcr > 60 ml min(-1) . CONCLUSION: In conclusion, the recommended doses of intravenous VFL administered once every 3 weeks in cancerpatients with renal impairment are 280 mg m(-2) when CLcr is between 40 and 60 ml min(-1) and 250 mg m(-2) when CLcr is between 20 and <40 ml min(-1) .
Authors: David J Vaughn; Sandy Srinivas; Walter M Stadler; Roberto Pili; Daniel Petrylak; Cora N Sternberg; David C Smith; Sarah Ringuette; Edwin de Wit; Virginie Pautret; Claude George Journal: Cancer Date: 2009-09-15 Impact factor: 6.860
Authors: J Bennouna; J-L Breton; J-M Tourani; C Ottensmeier; M O'Brien; P Kosmidis; T E Huat; M-C Pinel; C Colin; J-Y Douillard Journal: Br J Cancer Date: 2006-05-22 Impact factor: 7.640
Authors: Analía Azaro; Jordi Rodón; Jean-Pascal Machiels; Sylvie Rottey; Silvia Damian; Richard Baird; Javier Garcia-Corbacho; Ron H J Mathijssen; Pierre-François Clot; Claudine Wack; Liji Shen; Maja J A de Jonge Journal: Cancer Chemother Pharmacol Date: 2016-10-27 Impact factor: 3.333
Authors: M De Santis; P J Wiechno; J Bellmunt; C Lucas; W-C Su; L Albiges; C-C Lin; E Senkus-Konefka; A Flechon; L Mourey; A Necchi; W C Loidl; M M Retz; N Vaissière; S Culine Journal: Ann Oncol Date: 2015-12-16 Impact factor: 32.976